12/4
04:50 pm
vnda
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness [Yahoo! Finance]
Medium
Report
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness [Yahoo! Finance]
12/4
04:21 pm
vnda
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
Low
Report
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
12/1
07:20 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/29
12:31 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by analysts at
Wall S
Medium
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by analysts at
Wall S
11/28
07:34 am
vnda
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness [Yahoo! Finance]
Low
Report
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness [Yahoo! Finance]
11/28
07:00 am
vnda
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
Medium
Report
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
11/21
03:33 am
vnda
Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality [Seeking Alpha]
Medium
Report
Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality [Seeking Alpha]
11/19
08:07 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
11/19
02:15 am
vnda
Vanda Pharmaceuticals (VNDA) Is Up 21.3% After Tradipitant Shows Promise in Reducing Wegovy Side Effects [Yahoo! Finance]
Medium
Report
Vanda Pharmaceuticals (VNDA) Is Up 21.3% After Tradipitant Shows Promise in Reducing Wegovy Side Effects [Yahoo! Finance]
11/17
07:16 pm
vnda
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting [Yahoo! Finance]
High
Report
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting [Yahoo! Finance]
11/17
06:37 pm
vnda
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
High
Report
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
11/6
06:57 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Low
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by analysts at B. Riley to a "strong-buy" rating.
11/5
05:00 pm
vnda
Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
Low
Report
Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
11/5
07:19 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) is now covered by analysts at B. Riley. They set a "buy" rating on the stock.
Low
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) is now covered by analysts at B. Riley. They set a "buy" rating on the stock.
11/1
01:05 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by analysts at
Wall Str
Low
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by analysts at
Wall Str
10/30
10:41 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) had its price target lowered by analysts at Cantor Fitzgerald from $13.00 to $11.00. They now have an "overweight" rating on the stock.
Medium
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) had its price target lowered by analysts at Cantor Fitzgerald from $13.00 to $11.00. They now have an "overweight" rating on the stock.
10/29
04:01 pm
vnda
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
High
Report
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
10/22
04:30 pm
vnda
Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025
Low
Report
Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025
10/13
09:35 am
vnda
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 [Yahoo! Finance]
Low
Report
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 [Yahoo! Finance]
10/8
10:11 am
vnda
New York Islanders Name Vanda Pharmaceuticals as Team's Jersey Patch Partner in Milestone NHL Agreement [Yahoo! Finance]
Low
Report
New York Islanders Name Vanda Pharmaceuticals as Team's Jersey Patch Partner in Milestone NHL Agreement [Yahoo! Finance]
10/8
08:28 am
vnda
Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena [Yahoo! Finance]
Low
Report
Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena [Yahoo! Finance]
10/8
08:00 am
vnda
Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena
Low
Report
Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena
10/1
05:14 pm
vnda
Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration [Yahoo! Finance]
Medium
Report
Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration [Yahoo! Finance]
10/1
05:02 pm
vnda
Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration
Medium
Report
Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration
9/29
04:24 pm
vnda
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14 [Yahoo! Finance]
Low
Report
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14 [Yahoo! Finance]